Fig. 5: Electrical and pharmacological cardioversion of atrial arrhythmias. | Nature Communications

Fig. 5: Electrical and pharmacological cardioversion of atrial arrhythmias.

From: Generating ring-shaped engineered heart tissues from ventricular and atrial human pluripotent stem cell-derived cardiomyocytes

Fig. 5

a, b Activation maps of the arrhythmogenic atrial EHTs, during arrhythmia and after conversion to normal rhythm by 10 µM flecainide (a) or 30 µM vernakalant (b) treatments. c Percentage of successful arrhythmia termination in the atrial EHTs following field stimulation (n = 30, biologically independent samples) or the addition of 10 µM flecainide (n = 9, biologically independent samples) or 30 µM verankalant (n = 17, biologically independent samples). *p < 0.05, Fisher test. d Success rate (%) in maintaining normal rhythm at 15 min after cardioversion without any treatment (n = 26, biologically independent samples), with flecainide treatment (n = 7, biologically independent samples) and with verankalant treatment (n = 9, biologically independent samples). **p < 0.01, ****p < 0.0001, Fisher test.

Back to article page